Trial Profile
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Risedronic acid
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 15 Jun 2013 Primary analysis presented at the 14th Annual Congress of the European League Against Rheumatism.
- 03 Nov 2012 Status changed from active, no longer recruiting to completed.
- 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.